These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprint.pdf (595.01 kB)

Design and Synthesis of Novel Peptidomimetics for Cancer Immunotherapy

submitted on 10.09.2020, 10:43 and posted on 10.09.2020, 11:48 by Ceyda Köse, Esra Uysal, Büşra Yazıcı, Zeynep Tuğay, Serap İpek Dingiş Birgül, Hamdullah Yanık, Ece Tavukcuoglu, Sevgi Gulyuz, Atilla Akdemir, Güneş Esendağlı, Özgür Yılmaz, Onur Alptürk
Tumor cells benefit from some certain signals, which are referred to as “immune checkpoints”, to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an adaptative immune response against tumoral cells. In this study, we have designed and synthesized some novel peptidomimetics with a 2-aminobenzathiazole scaffold, which targets the PD-1/PDL-1 pathway. In the viability assay, it was found that these compounds decreased the proliferation of peripheral blood mononuclear cells in the concentration of 10 uM. Overall, our results indicate that these novel compounds are potential checkpoint inhibitors for cancer immunotherapy.


Turkish Scientific and Technological Council (project numbers: TUBITAK-116E661)

Turkish Scientific and Technological Council (project numbers: TUBITAK-116E662)

Turkish Scientific and Technological Council (project numbers: TUBITAK-116E644)


Email Address of Submitting Author


Istanbul Technical University



ORCID For Submitting Author


Declaration of Conflict of Interest

no conflict of interest